Advancements in Personalized Cellular Immunotherapy

Arun Kumar Singh is Assistant Professor in the Department of Pharmacy at Vivekanand Global University, India. His teaching and research activities span pharmaceutical sciences and a range of interdisciplinary fields, including nanoformulation, cancer biology, artificial intelligence, machine learning, blockchain technology, the Internet of Things, big data analytics, and neuroscience. He has contributed to scholarly publishing through authorship and editorial work and has participated in research and academic initiatives that integrate emerging technologies with healthcare and pharmaceutical applications. His interests focus on advancing innovative approaches to drug delivery, biomedical research, and technology-enabled solutions for healthcare challenges. Dr. Murali Yallapu is a tenured Professor at the University of Texas Rio Grande Valley's School of Medicine, specializing in Immunology, Microbiology,Toxicology and Oncology and a member of the South Texas Center of Excellence in Cancer Research. Dr. Yallapu received the "Prof. A. Kameswara Rao's Gold Medal-1999" and completed postdoctoral training in materials science, drug delivery, nanomedicine, and cancer biology at institutions including the Cleveland Clinic and the University of Nebraska Medical Center. Before joining UTRGV, he was an Assistant Professor at the University of Tennessee Health Science Center. Dr. Yallapu serves on editorial boards for various journals related to drug delivery, nanotechnology, and cancer, and is an ad-hoc reviewer for the NIH and other funding agencies. He has published over 190 peer-reviewed articles and reviews. His current research primarily focuses on the development of nanomaterials for improved therapeutic potential of clinical drug(s) and developing new constructs for biomedical applications. Additionally, through Cancer Immunology Institute, he is working to generate safe and effective nanoformulations for cancer immunotherapy. Dr.Ciniraj is presently working as an Associate Professor at Medical College Thiruvananthapuram, Kerala, India, one of the largest multispecialty tertiary care hospitals in southern India. He undertakes teaching courses in oncology for undergraduate and postgraduate students. As a permanent faculty member appointed by the government of Kerala State, he is actively involved in patient care, curriculum development, teaching and evaluation, and clinical research. He actively participates in national and international conferences and institutional research methodology workshops. Currently, he undertakes research projects in clinical oncology at multiple government institutions as primary investigator. He also works as a guide to postgraduate thesis and assists them in their research work. He has a deep interest in oncology research and has published a few original research articles in clinical oncology, which are indexed in Scopus and PubMed. He has reviewed over 100 medical articles for leading publishers, including Elsevier, Springer, and British Medical JournalPranav Kumar Prabhakar is Professor and Head of the Department of Biotechnology, School of Engineering and Technology, Nagaland University, Kohima, India. His research focuses on understanding molecular mechanisms involved in metabolic disorders, particularly diabetes, and on developing strategies for oral insulin delivery using natural products and biotechnology-based approaches. He is actively involved in research, academic mentoring, peer review, and editorial activities within the biomedical and biotechnology fields. His professional interests include translational research, signaling pathways associated with metabolic diseases, and the application of biotechnology to improve therapeutic outcomes. He contributes to scientific and academic initiatives that support advancements in biotechnology and healthcare research.

• 1. Introduction to Personalized Cellular Immunotherapy2. Understanding the therapeutic significance of tumor-infiltrating immune cells and their characteristics: a historical overview of cancer immunotherapy3. A groundbreaking development in cancer treatment: chimeric antigen receptor CART-cell therapy4. Recent Progress in CAR-T Cell Therapy for B Cell Cancers with Resistant Tissues5. Targeting the tumor vasculature using mesenchymal stem cells in cancer therapy: new perspectives6. The use of oncolytic viruses delivered by mesenchymal stromal cells in immunotherapy for the treatment of metastatic tumors7. Cancer Treatment Advancements in the Era of Immune Checkpoint Inhibitors via Cellular Immunotherapies8. The future of cancer immunotherapy: combining gene and cellular approaches9. Platelet Shielding of Cancer Cells: Implications for Immunotherapy Strategies10. Cancer Cell-Platelet Interactions: Harnessing Therapeutic Opportunities in Cancer Treatment11. Myeloid-Derived Suppressor Cells: A Promising Target for Anticancer Immunotherapy12. Utilizing Nanomedicines to Modulate Myeloid-Derived Suppressor Cells: Enhancing Cancer Immunotherapy13. Unlocking the Potential of Macrophages: Advancements in Cellular Immunotherapy14. Combination therapy: a new strategy to manage cancer15. Future perspective of cellular immunotherapy in cancer treatment

Select Guide Rating